TINAVI(SH:688277)2021-04-09 16:00Financial Performance - The company reported a total revenue of RMB 100 million for the year 2020, marking a year-on-year increase of 20%[12]. - The company's operating revenue for 2020 was CNY 135,909,532.98, a decrease of 40.80% compared to the previous year[19]. - The net profit attributable to shareholders was a loss of CNY 54,470,877.18, which represents an increase in loss of 75.95% year-on-year[21]. - The net cash flow from operating activities decreased by 380.43% to CNY -57,578,159.36, primarily due to a decline in sales revenue[21]. - The total expenses for the period were CNY 20,920.98 million, a decrease of 19.78% compared to the previous year[21]. - The company achieved operating revenue of CNY 135.91 million, a year-on-year decrease of 40.80%[84]. - The net profit loss was CNY 54.17 million, an increase in loss of 58.53% year-on-year[84]. - The company's main business revenue in the medical device sector was CNY 126.88 million, with a year-on-year decrease of 43.47%[108]. - The orthopedic surgical navigation robot generated sales revenue of CNY 111.59 million, accounting for 87.95% of the main business revenue, with a year-on-year decrease of 47.74%[108]. Research and Development - The company is investing RMB 20 million in R&D for new technologies aimed at enhancing product efficiency[12]. - Research and development expenses accounted for 54.53% of operating revenue, an increase of 20.98 percentage points from the previous year[20]. - The total R&D investment for the year was approximately ¥74.11 million, a decrease of 3.76% compared to the previous year, while the R&D investment as a percentage of operating revenue increased by 20.98 percentage points to 54.53%[66]. - The company has submitted 72 new patent applications during the reporting period, including 30 invention patents, and has obtained 50 new patent authorizations, with 6 being invention patents[62]. - The company has developed high-precision online calibration technology for surgical robots, with an error requirement of less than 0.5 mm[47]. - The company has achieved significant advancements in the development of core components for the orthopedic surgical robot, including the medical robot-specific manipulator and optical tracking camera[63]. - The company has developed a modular design technology for surgical tools, enabling the orthopedic surgical robot to perform over ten different surgical procedures, with ongoing expansion[55]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by 2023[12]. - The company aims to reshape orthopedic surgical processes through intelligent methods, integrating all relevant technological elements into a smart orthopedic platform[33]. - The company is focused on establishing orthopedic surgical robot minimally invasive surgery centers in collaboration with medical institutions[149]. - The company plans to continue promoting its products in the Huazhong and Southwest regions, where revenue has seen some growth due to channel expansion efforts[110]. - The company is exploring partnerships to enhance distribution channels, aiming for a 25% increase in reach by the end of the next fiscal year[159]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm, ensuring the accuracy of its financial statements[5]. - There are no plans for profit distribution or capital increase through reserves for the reporting period[5]. - The company has committed to not transferring or entrusting the management of its pre-IPO shares for 36 months from the date of listing[157]. - The company will adhere to the regulations set forth by the China Securities Regulatory Commission regarding share rights and interests adjustments[157]. - The company has established a commitment to bear any economic liabilities related to employee social insurance contributions prior to its IPO[161]. Customer Engagement and Satisfaction - User data showed a growth of 25% in active users year-over-year, indicating strong customer engagement[159]. - Customer satisfaction ratings improved by 15%, indicating successful implementation of new service strategies[158]. Financial Management and Investments - The company raised a total of 100 million RMB through structured deposits from fundraising sources[184]. - The company has a strategy focused on diversifying its investment portfolio through various financial instruments[186]. - The company is actively managing its financial products to optimize returns and liquidity[185]. - The company has committed to strengthening the management of raised funds to prevent usage risks[163]. Social Responsibility - The company donated 100,000 RMB to support medical institutions in Hubei for purchasing epidemic prevention materials during the COVID-19 outbreak[198]. - The company contributed 200,000 RMB to assist in poverty alleviation efforts in Yushu Prefecture, Qinghai Province[198]. - The company invested 3 million RMB in the "Beijing Natural Science Fund - Haidian Original Innovation Joint Fund" to support key projects in the smart orthopedic field[198].